Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

Being treated for childhood cancer set Jason Schwartz on the path to his life’s work: treating childhood cancer

Cancer at the age of 13 forced him to give up his dream of professional football. While undergoing treatment, he found a new dream.

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

Children’s Hospital patients get creative for Vanderbilt Men’s Basketball team as part of Coaches vs. Cancer

Cell signaling targets in leukemia

Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.